Experimental study in?vitro.
University hospital.
Seventeen patients with ovarian endometrioma.
ESCs from chocolate cyst linings of ovaries were treated with DNG.
Expression of aromatase and COX-2 evaluated in spheroid cultures of human ESCs by real-time quantitative polymerase chain-reaction and immunocytochemistry, production of PGE2 quantified by enzyme-linked immunosorbent assay (ELISA), and nuclear factor kappa B (NF-¦ÊB) DNA-binding examined by ELISA and immunocytochemistry.
The pharmaceutical actions of DNG on the expression of aromatase and COX-2 and the production of PGE2 were examined using spheroid cultures of human ESCs. More aromatase, COX-2, and PGE2 were expressed in spheroid cultures than in conventional ESCs monolayers. In the spheroid cultures, DNG (10?7 M) and progesterone (10?7 M) inhibited the expression of aromatase, COX-2, and PGE2. DNG also inhibited NF-¦ÊB DNA-binding activity and reduced the immunocytochemical protein expression of aromatase, COX-2, and NF-¦ÊB p50 nuclear localization.
Because DNG inhibits aromatase and COX-2 expression as well as PGE2 production in ESCs, these pharmacologic features might contribute to a therapeutic effect of DNG on endometriosis.